Animal Models of Disease Part C

1st Edition, Volume 192 - January 24, 2025
Editors: Lorenzo Galluzzi, Fernando Aranda Vega, Aitziber Buque Martinez, Jose Manuel Bravo-San Pedro
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 2 2 2 4 2 - 9
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 2 2 2 4 3 - 6

Animal Models of Disease, Part C, Volume 192 in the Methods in Cell Biology series, highlights advances in the field, with this new volume presenting interesting chapters on a… Read more

Purchase options

Institutional subscription on ScienceDirect

Request a sales quote

Animal Models of Disease, Part C, Volume 192 in the Methods in Cell Biology series, highlights advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors, The current models unravel the molecular mechanisms underlying the intricate pathophysiology of Alzheimer’s disease using Zebrafish, Colitis mouse model, Matching model with mechanism: appropriate animal models for studying various aspects of diabetes pathophysiology, Human cancer cells xenografts to assess the efficacy of granulysin-based therapeutics, and much more.

Additional sections cover Antimicrobial regime for gut microbiota depletion in experimental mice models, Evaluating polyglutamine protein aggregation and toxicity in transgenic Caenorhabditis elegans models of Huntington's disease, A model of intraperitoneal ovarian cancer to study tumor responses to radioimmunotherapy, Metallic nanoparticles biodistribution for the study of lymphoma in animal models, Stereotactic injection of murine brain tumor cells for neuro-oncology studies, Evaluating amyloid-beta aggregation and toxicity in transgenic Caenorhabditis elegans models of Alzheimer's disease, and much more.

Animal Models of Disease - Part C
Cover image
Title page
Table of Contents
Series Page
Copyright
Contributors
Animal models of disease: Achievements and challenges
Competing interests
References
Chapter One Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors
Abstract
Keywords
1 Introduction
2 Key resource table
3 Detailed methods
3.1 General considerations before starting your experiment
4 Discussion
Acknowledgments
References
Chapter Two The current models unravel the molecular mechanisms underlying the intricate pathophysiology of Alzheimer's disease using zebrafish
Abstract
Keyword
1 Introduction
2 Chemical-induced AD in Zebrafish
2.1 Okadaic acid-induced AD
2.2 Amyloid beta-induced AD
3 Discussion and conclusion
Conflict of interest
References
Chapter Three A mouse model to assess immunotherapy-related colitis
Abstract
Keywords
1 Introduction
2 Materials
2.1 Mice
2.2 Reagents and equipment
2.3 Software
3 Protocol
3.1 Treatments
3.2 Colitis evaluation
4 Concluding remarks
Declaration of competing interest
References
Chapter Four Matching model with mechanism: Appropriate rodent models for studying various aspects of diabetes pathophysiology
Abstract
Keywords
1 Introduction
2 Modeling autoimmunity
3 Modeling insulin resistance and adiposity
4 Models of specific beta cell pathogenesis
4.1 Modeling beta cell dysfunction/impaired beta cell compensation
4.2 Modeling loss of beta cell mass
5 Conclusion
References
Chapter Five Induction of sepsis in a rat model by the cecal ligation and puncture technique. Application for the study of experimental acute renal failure
Abstract
Keywords
1 Introduction
2 Objective
3 Materials
3.1 Surgical material
3.2 Reagents/drugs
3.3 Software and equipments
4 Surgical procedure
4.1 Pre-surgery
4.2 Surgery
4.3 Post-surgery
5 Sepsis-induced ARF in rat model
6 Conclusions
Acknowledgments and funding
References
Chapter Six Human cancer cells xenografts to assess the efficacy of granulysin-based therapeutics
Abstract
Keywords
1 Introduction
2 Materials
2.1 Common disposables
2.2 Cells
2.3 Mice
2.4 Reagents
2.5 Equipment
2.6 Software
3 Methods
3.1 Anesthesia (see Notes 7 and 8)
3.2 Euthanasia (see Note 9)
3.3 Subcutaneous injection of human cancer cells in nude mice (see Notes 7, 8 and 12)
3.4 Monitoring tumor growth
3.5 Tumor growth test (see Notes 7, 8 and 12)
3.6 Treatment administration (see Notes 7, 8 and 12)
3.7 Analysis of the possible toxic effects of the treatment (see Notes 7, 8, 12 and Fig. 1)
3.8 Antitumor effect of the treatments (see Notes 7, 8, 12 and Fig. 2)
3.9 Tumor extraction
3.10 Data analysis
4 Notes
5 Concluding remarks
Conflicts of interest
References
Chapter Seven Antimicrobial regime for gut microbiota depletion in experimental mice models
Abstract
Keywords
1 Introduction
2 Materials
3 Experimental protocol
3.1 Antibiotic preparation
3.2 Considerations prior to animal experimentation
3.3 Stool samples collection
3.4 Mouse antibiotic administration
3.5 Fecal sample processing
4 Expected outcome
5 Concluding remarks
References
Chapter Eight Evaluating polyglutamine protein aggregation and toxicity in transgenic Caenorhabditis elegans models of Huntington's disease
Abstract
Keywords
1 Introduction
2 Materials
2.1 General laboratory supplies
2.2 Reagents
2.3 C. elegans strains
2.4 Software and equipment
3 Methods
3.1 C. elegans culture and maintenance
3.2 Imaging and quantification of polyQ-mediated protein aggregation
3.3 Imaging and assessment of polyQ-mediated neurotoxicity
3.4 Analysis of polyQ-mediated behavioral dysfunctions
4 Concluding remarks
5 Notes
Acknowledgments
References
Chapter Nine Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing
Abstract
Keywords
1 Introduction
2 Materials
2.1 Disposables
2.2 Reagents
2.3 Equipment
2.4 Reagent preparation
3 Forewords
4 Cell maintenance and bioluminescence imaging in vitro
5 Establishment of the ovarian cancer peritoneal carcinomatosis model
6 Calibration between tumor mass and bioluminescence signal
7 Antibody bioconjugation and radiolabeling with lutetium-177
7.1 Coupling the bifunctional chelate
7.2 Radiolabeling
8 In vivo TRT and assessment of the response to TRT
9 Concluding remarks
10 Notes
Disclosures
References
Chapter Ten Metallic nanoparticles biodistribution for the study of lymphoma in animal models
Abstract
Keywords
1 Introduction
2 Materials
3 Equipment
4 Nanoparticles synthesis and characterization
4.1 AuNPs synthesis protocol (Bastús et al., 2011)
4.2 Hollow gold silver nanoparticles (AuAgNPs) synthesis protocol (Bastús et al., 2014; Russo et al., 2018)
5 Nanoparticles suspension preparation according to administration routes
5.1 Oral administration
5.2 Intravenous administration (i.v.)
5.3 Intraperitoneal administration (i.p.)
5.4 Intramuscular administration (i.m.)
6 Lymphoma model generation
6.1 NSG PDXs cell lymphoma model
7 Biodistribution studies
7.1 X-ray computerized tomography (CT)
7.2 Inductively coupled plasma mass spectrometry (ICP-MS), Elemental analysis
Acknowledgments
References
Chapter Eleven Stereotactic injection of murine brain tumor cells for neuro-oncology studies
Abstract
Keywords
1 Introduction
1.1 Material
1.2 Method
1.3 Intracranial cell injection
2 Conclusion
Conflict of interest statement
References
Chapter Twelve Evaluating amyloid-beta aggregation and toxicity in transgenic Caenorhabditis elegans models of Alzheimer’s disease
Abstract
Keywords
1 Introduction
2 Materials
2.1 General laboratory supplies
2.2 Reagents
2.3 Strains
2.4 Software and equipments
3 Methods
3.1 C. elegans culture and maintenance
3.2 Culture of transgenic strains and Aβ expression
3.3 Aβ quantification assays
3.4 Behavior analysis of Aβ-mediated toxicity
4 Concluding remarks
5 Notes
Acknowledgments
References

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Fernando Aranda Vega

Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.

Affiliations and expertise

Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

Aitziber Buque Martinez

Aitziber Buqué is currently a Post-Doctoral Associate with the Galluzzi Lab, in the Department of Radiation Oncology at Weill Cornell Medical College (New York), where she investigates innate and acquired mechanisms of resistance to immunotherapy in HR+ breast cancer and radiotherapy as a means to overcome them. Prior to joining the Galluzzi Lab (2018), Aitziber was a Post-Doctoral Associate with the Kroemer Lab in the Cordeliers Research Center (Paris, France; 2014-2018), after receiving her M.Sc. in Bioinformatics and Computational Biology (2006) from the Complutense University (Madrid, Spain) and her Ph.D. in Biomedicine (2013) from the BioCruces Research Institute (Barakaldo, Spain). Aitziber has a long-standing interest in the immunological mechanisms controlling cancer progression and response to treatment.

Affiliations and expertise

Postdoctoral Associate in Radiation Oncology, Radiation Oncology, Weill Cornell Medical College, NY, USA

Jose Manuel Bravo-San Pedro

Jose Manuel Bravo-San Pedro is currently a researcher at the Department of Physiology of the Complutense University of Madrid thanks to a Ramon y Cajal contract grant. He got his Ph.D. in biochemistry, cellular biology and genetics from the University of Extremadura (Caceres, Spain) in 2011, and he did a post-doctoral stage in the laboratory of Prof. Guido Kroemer. His main research interests have always been linked to autophagy, addressing this cellular process associated with neurodegenerative diseases or cancer and recently obesity and specifically related to problems in the correct functioning of the cilium. He is co-inventor of two patents and co-author of 110 publications indexed in PubMed in prestigious international journals, with h-index 45 and 23768 cites (Dec 2022).

Affiliations and expertise

Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Animal Models of Disease Part C

Purchase options

Institutional subscription on ScienceDirect

Lorenzo Galluzzi

Fernando Aranda Vega

Aitziber Buque Martinez

Jose Manuel Bravo-San Pedro